PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Tα1, Zadaxin
🛡ï¸Immune PeptideEnhances T-cell function, boosts dendritic cell activity, and modulates cytokine production. Shifts immune response toward effective pathogen clearance.
Garaci et al.: Review of Tα1 use in immune-compromised patients showing enhanced T-cell function, improved dendritic cell activity, and cytokine modulation.
moderate strongKing & Tuthill: Comprehensive review of 30+ clinical trials involving 11,000+ subjects confirming Tα1's consistent safety and efficacy across hepatitis B/C, cancer, and infections.
strongMutchnick et al. (Hepatology): Randomized trial showing Tα1 combined with interferon significantly improves virologic response in chronic hepatitis B vs. interferon alone.
strongEvidence review of Tα1 in septic shock, ARDS, and peritonitis showing improved survival and immune recovery in critically ill patients.
moderate strongGaraci et al. (Ann. N.Y. Acad. Sci.): Review of Tα1 as cancer immunotherapy adjunct, showing enhanced chemotherapy tolerance and improved immune recovery in multiple tumor types.
moderateApproved in 35+ countries for hep B/C. One of the most extensively studied peptides. Not FDA-approved in US.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Standard dose: 1.6mg 2x/week. Approved in 35+ countries. Higher doses for active infection.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
NK cell and T-cell activation begins; improved energy if immune-suppressed
Weeks 2-4
Enhanced immune response to pathogens; reduced frequency of illness
Month 2-3
Sustained immune modulation; improved recovery from illness
Long-term
Long-term immune resilience; approved use in 35+ countries for hepatitis therapy
| Side Effect | Incidence | Severity |
|---|---|---|
Injection site reaction | ~5% of users | mild |
Mild flu-like symptoms (immune activation) Indicates immune activation; usually transient | ~5% of users | mild |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Strengthen and modulate immune function for enhanced pathogen defense
Repair and protect the gastrointestinal lining and reduce GI inflammation
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.